102 related articles for article (PubMed ID: 8965895)
1. High-dose chemotherapy in multiple myeloma.
Atkins CD
N Engl J Med; 1996 Dec; 335(24):1844; author reply 1845. PubMed ID: 8965895
[No Abstract] [Full Text] [Related]
2. High-dose chemotherapy in multiple myeloma.
Oivanen TM; Palva IP
N Engl J Med; 1996 Dec; 335(24):1844-5; author reply 1845. PubMed ID: 8965896
[No Abstract] [Full Text] [Related]
3. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Attal M; Harousseau JL; Stoppa AM; Sotto JJ; Fuzibet JG; Rossi JF; Casassus P; Maisonneuve H; Facon T; Ifrah N; Payen C; Bataille R
N Engl J Med; 1996 Jul; 335(2):91-7. PubMed ID: 8649495
[TBL] [Abstract][Full Text] [Related]
4. Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma.
Patriarca F; Sperotto A; Filì C; Zaja F; Prosdocimo S; Fanin R
Haematologica; 2002 Jul; 87(7):779-81. PubMed ID: 12091134
[TBL] [Abstract][Full Text] [Related]
5. [On the road to cure of multiple myeloma?].
Löwenberg B; Sonneveld P
Ned Tijdschr Geneeskd; 1992 Apr; 136(14):669-71. PubMed ID: 1560851
[No Abstract] [Full Text] [Related]
6. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Child JA; Morgan GJ; Davies FE; Owen RG; Bell SE; Hawkins K; Brown J; Drayson MT; Selby PJ;
N Engl J Med; 2003 May; 348(19):1875-83. PubMed ID: 12736280
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma.
Murakami H; Fujii H; Inaba T; Shimazaki C; Okamoto S; Miwa A; Sawamura M; Abe M; Chou T; Asaoku H; Kitahara Y; Hayashi K; Kosaka M; Togawa A; Takatsuki K;
Eur J Haematol; 2004 Sep; 73(3):169-73. PubMed ID: 15287913
[TBL] [Abstract][Full Text] [Related]
8. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
9. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
[TBL] [Abstract][Full Text] [Related]
10. [Advances in treatment of multiple myeloma].
Gola A
Acta Haematol Pol; 1992; 23(4):229-35. PubMed ID: 1293903
[TBL] [Abstract][Full Text] [Related]
11. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
12. [Multiple myeloma in 1990].
Le Loët X; Monconduit M; Euller-Ziegler L
Ann Med Interne (Paris); 1990; 141(2):108-10. PubMed ID: 2191611
[No Abstract] [Full Text] [Related]
13. Transplantation in multiple myeloma.
Topolsky D; Biggs D
Semin Oncol; 1995 Jun; 22(3):230-7. PubMed ID: 7777867
[No Abstract] [Full Text] [Related]
14. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.
Haas PS; Bauchmüller K; Kühnemund A; Finke J; Ihorst G; Engelhardt M
Ann Hematol; 2006 Mar; 85(3):191-3. PubMed ID: 16365747
[No Abstract] [Full Text] [Related]
16. [Multiple myeloma--new therapeutic perspectives].
Skotnicki AB; Wolska-Smoleń T; Jurczyszyn A
Przegl Lek; 1999; 56 Suppl 1():67-72. PubMed ID: 10494186
[TBL] [Abstract][Full Text] [Related]
17. [Intensive treatment of multiple myeloma].
Harousseau JL
Bull Acad Natl Med; 2003; 187(2):405-13; discussion 413-5. PubMed ID: 14556449
[TBL] [Abstract][Full Text] [Related]
18. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma.
Bakkus MH; Bouko Y; Samson D; Apperley JF; Thielemans K; Van Camp B; Benner A; Goldschmidt H; Moos M; Cremer FW
Br J Haematol; 2004 Sep; 126(5):665-74. PubMed ID: 15327517
[TBL] [Abstract][Full Text] [Related]
19. [Recent therapy for refractory myeloma].
Togawa A
Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of multiple myeloma].
La Verde G; Pulsoni A; Petrucci MT; Mandelli F
Recenti Prog Med; 1997 Apr; 88(4):186-93. PubMed ID: 9206817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
